| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (NCT04924608) | AstraZeneca | 2021-11-19 |
| RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada (NCT05933044) | AstraZeneca | 2021-11-19 |
| Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants (NCT05134727) | AstraZeneca | 2021-11-18 |
| Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat (NCT05961384) | AstraZeneca | 2021-11-18 |
| AZD9833 China PK Study (NCT04818632) | AstraZeneca | 2021-11-12 |
| VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19 (NCT05084755) | AstraZeneca | 2021-11-11 |
| Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (NCT04774380) | AstraZeneca | 2021-11-11 |
| A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment (NCT05112419) | AstraZeneca | 2021-11-10 |
| Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate (NCT04814680) | AstraZeneca | 2021-11-08 |
| Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT05008055) | AstraZeneca | 2021-11-03 |
| Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer (NCT04808050) | AstraZeneca | 2021-11-03 |
| IBS-C Questionnaire Study (NCT04968652) | AstraZeneca | 2021-11-01 |
| CLL Therapy Approaches in Russia (NCT05140369) | AstraZeneca | 2021-10-29 |
| A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations (NCT05048797) | AstraZeneca | 2021-10-28 |
| Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (NCT05113251) | AstraZeneca | 2021-10-25 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies (NCT05123482) | AstraZeneca | 2021-10-18 |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (NCT05104866) | AstraZeneca | 2021-10-18 |
| A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours (NCT04958226) | AstraZeneca | 2021-10-15 |
| A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults (NCT05437289) | AstraZeneca | 2021-10-09 |
| MEOI and HRQoL in CLL Patients Treated With BTKis (NCT04938141) | AstraZeneca | 2021-10-07 |
| Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres (NCT05932849) | AstraZeneca | 2021-10-05 |
| Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam (NCT05052710) | AstraZeneca | 2021-10-05 |
| A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (NCT05056727) | AstraZeneca | 2021-09-30 |
| Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer (NCT04801186) | AstraZeneca | 2021-09-28 |
| A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (NCT04931654) | AstraZeneca | 2021-09-28 |
| A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (NCT04995523) | AstraZeneca | 2021-09-14 |
| A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours (NCT04949425) | AstraZeneca | 2021-09-13 |
| Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE) (NCT04931563) | AstraZeneca | 2021-09-13 |
| A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (NCT04765059) | AstraZeneca | 2021-09-12 |
| Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants (NCT05070312) | AstraZeneca | 2021-08-23 |
| Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma (NCT05062759) | AstraZeneca | 2021-08-23 |
| Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England (NCT05047822) | AstraZeneca | 2021-08-23 |
| Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (NCT04989816) | AstraZeneca | 2021-08-20 |
| Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia (NCT04997161) | AstraZeneca | 2021-08-17 |
| A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab (NCT04884269) | AstraZeneca | 2021-08-11 |
| Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment (NCT05961397) | AstraZeneca | 2021-08-10 |
| Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes (NCT07159295) | AstraZeneca | 2021-08-10 |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (NCT04960709) | AstraZeneca | 2021-08-05 |
| Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants (NCT04991571) | AstraZeneca | 2021-07-29 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers (NCT04994106) | AstraZeneca | 2021-07-27 |
| Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE) (NCT05001698) | AstraZeneca | 2021-07-27 |
| Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants (NCT04944771) | AstraZeneca | 2021-07-26 |
| Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis (NCT05006573) | AstraZeneca | 2021-07-21 |
| Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas (NCT05101148) | AstraZeneca | 2021-07-21 |
| Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma (NCT04930536) | AstraZeneca | 2021-07-14 |
| Technology-Assisted Cholesterol Trial in Consumers (TACTiC) (NCT04964544) | AstraZeneca | 2021-07-08 |
| A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia (NCT04964557) | AstraZeneca | 2021-07-07 |
| Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% (NCT04986202) | AstraZeneca | 2021-06-30 |
| Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation (NCT04872621) | AstraZeneca | 2021-06-30 |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (NCT04964934) | AstraZeneca | 2021-06-30 |
| Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers (NCT04798222) | AstraZeneca | 2021-06-29 |
| A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib (NCT04959266) | AstraZeneca | 2021-06-28 |
| A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (NCT04870112) | AstraZeneca | 2021-06-28 |
| Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (NCT04973449) | AstraZeneca | 2021-06-27 |
| Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom (NCT04667312) | AstraZeneca | 2021-06-24 |
| Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (NCT05171816) | AstraZeneca | 2021-06-24 |
| Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults (NCT04840849) | AstraZeneca | 2021-06-22 |
| Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer (NCT04830709) | AstraZeneca | 2021-06-15 |
| Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies (NCT04865419) | AstraZeneca | 2021-06-11 |
| Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (NCT04877691) | AstraZeneca | 2021-06-08 |
| D9319C00001- 1L OC Mono Global RCT (NCT04884360) | AstraZeneca | 2021-05-31 |
| Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222 (NCT04877743) | AstraZeneca | 2021-05-31 |
| Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status (NCT04807595) | AstraZeneca | 2021-05-28 |
| LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS) (NCT04889404) | AstraZeneca | 2021-05-22 |
| Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis (NCT04799067) | AstraZeneca | 2021-05-17 |
| Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer (NCT04857619) | AstraZeneca | 2021-05-14 |
| Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations (NCT05103605) | AstraZeneca | 2021-05-12 |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (NCT04862663) | AstraZeneca | 2021-05-10 |
| Forxiga HF General Drug Use-Results Study (NCT04865406) | AstraZeneca | 2021-05-10 |
| A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. (NCT03528681) | AstraZeneca | 2021-05-06 |
| Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer (NCT04991051) | AstraZeneca | 2021-05-02 |
| Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) (NCT04847232) | AstraZeneca | 2021-04-30 |
| Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (NCT05169619) | AstraZeneca | 2021-04-30 |
| Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (NCT04724837) | AstraZeneca | 2021-04-28 |
| Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform (NCT04868500) | AstraZeneca | 2021-04-27 |
| Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) (NCT04784715) | AstraZeneca | 2021-04-26 |
| IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer (NCT04854590) | AstraZeneca | 2021-04-22 |
| Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (NCT04851964) | AstraZeneca | 2021-04-22 |
| HRR Prevalence in LatAm PROSPECT Study (NCT04962880) | AstraZeneca | 2021-04-21 |
| US PRECISION Implementation Study (NCT04891978) | AstraZeneca | 2021-04-20 |
| Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers (NCT04770428) | AstraZeneca | 2021-04-20 |
| A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol (NCT04550234) | AstraZeneca | 2021-04-13 |
| A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects. (NCT04856007) | AstraZeneca | 2021-04-12 |
| To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients (NCT04445714) | AstraZeneca | 2021-04-07 |
| Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects (NCT04788641) | AstraZeneca | 2021-03-30 |
| Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NCT04727528) | AstraZeneca | 2021-03-22 |
| Phase I Double-blind, Placebo-controlled Study of AZD7442 (NCT04896541) | AstraZeneca | 2021-03-16 |
| Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice (NCT04536402) | AstraZeneca | 2021-03-16 |
| Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients (NCT04560452) | AstraZeneca | 2021-03-15 |
| Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids (NCT04643158) | AstraZeneca | 2021-03-12 |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (NCT04686305) | AstraZeneca | 2021-03-09 |
| Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (NCT04676646) | AstraZeneca | 2021-03-08 |
| A Study of CIN-107 in Adults With Primary Aldosteronism (NCT04605549) | AstraZeneca | 2021-03-08 |
| Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer (NCT04742192) | AstraZeneca | 2021-03-04 |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (NCT04594642) | AstraZeneca | 2021-03-02 |
| Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (NCT04609904) | AstraZeneca | 2021-03-01 |
| Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study (NCT04991805) | AstraZeneca | 2021-02-26 |
| Study of AZD2811 + Durvalumab in ES-SCLC (NCT04745689) | AstraZeneca | 2021-02-23 |
| Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma (NCT04673630) | AstraZeneca | 2021-02-23 |
| Capivasertib China PK Study (NCT04742036) | AstraZeneca | 2021-02-22 |